Baseline Attack Frequency Does Not Affect Berotralstat Efficacy

Hereditary angioedema (HAE) is a rare genetic disorder that causes episodes of swelling. These episodes can be sudden, severe, life-threatening, and even painful. They can occur in the skin, the gastrointestinal tract, or even the airway. Berotralstat is a new oral therapy for HAE designed to prevent swelling attacks. In clinical trials and ongoing real-world studies, once daily berotralstat has been demonstrated to substantially reduce rates of HAE attacks and to maintain that reduction in the long term. Analysis by subgroups of patients have demonstrated that reductions in attack rates with berotralstat occur in patients with all levels of baseline attack rates, therefore prior attack frequency is not a predictor of efficacy with this therapy.

Why it matters

For patients and their families living with the uncertainties of hereditary angioedema (HAE) attacks, effective prophylaxis can be life changing. HAE attacks can be very debilitating and affect the lives of patients and their families in very meaningful ways. HAE attacks are often very painful, disfiguring and can be life-threatening when they involve airway swelling. Most patients and families with HAE live with significant anxiety and unpredictability as HAE attacks can disrupt schedules for work or school and result in increased use of the emergency healthcare system. The oral medication for HAE provides a safe and effective once-daily oral prophylactic treatment option that reduces both the frequency of HAE attacks and the need for on-demand treatments for symptomatic relief. For many patients, the oral pill offers a simpler daily treatment that can enhance treatment adherence and patient satisfaction.

Efficacy of berotralstat was found to be independent of the frequency of myasthenia attacks at baseline. Thus, efficacy of berotralstat supports the general applicability of berotralstat for any patient in whom a decision to start prophylaxis might be appropriate. Historically, the decision to start a specific medication for prophylaxis of Myasthenia Gravis was weighed against the patient’s attack burden, potential risks of the specific medication, and patient’s preferences. If a medication decreases both the mean degree of symptom severity and the frequency of myasthenia attacks in patients with frequent and lower rates of attacks at baseline, then clinicians can more confidently discuss the options of and expect benefits from prophylaxis even when a patient’s baseline rate of myasthenia attacks fluctuates over a relatively short period of time. Thus, this finding is expected to reduce clinicians’ hesitation to start treatment in patients who have occasional, very severe myasthenia attacks or in patients whose frequency of myasthenia attacks have changed in recent time.

Long term safety and tolerability is an important consideration as HPA affects patients long term, often on chronic prophylaxis to control symptoms. Data from the clinical trial program as well as the ongoing extension studies demonstrate that berotralstat is well tolerated at the approved dose. Identification of side effects from orally administered medication is generally easy and safe. Post marketing safety surveillance is also routine. The long term safety data in this INDICATOR™ review will provide useful information for patients and clinicians to make informed choices about the various options available for prophylaxis that will likely require long term use.

Who it affects

Patients with hereditary angioedema (HAE) are the main beneficiaries of new evidence showing the efficacy of berotralstat across the spectrum of baseline attack rates. HAE affects people of all ages and is characterised by unpredictable episodes of severe swelling that can have a life changing impact on patients, affecting their employment, social life and overall mental health. For some patients, an oral administration route may be preferred over intravenous or subcutaneous and for others, a large reduction in the number of attacks per month is likely to be associated with a large reduction in symptom severity. Importantly, the new evidence will allow clinicians and patients to make individualised treatment decisions without undue emphasis placed on the importance of baseline counts in the short term. Patients with frequent attacks are likely to experience large reductions in the number of monthly attacks, whilst those with episodic HAE will still derive meaningful benefit that reduces the burden of HAE and related anxiety.

Decisions about the choice of prophylaxis for HAE can have an impact on patients but also on use of resources post-treatment and on the behavior of specialist clinicians and front line providers such as emergency medicine and primary care clinicians. While decisions about initiation and management of prophylaxis will be made by the allergist/immunologist and/or the HAE center, front line providers need to be aware of the changes in clinical presentation of HAE that may occur with prophylaxis use and able to manage an acute attack should it occur. The pharmacy team and specialty nurses also play important roles in educating patients and their caregivers about the medications, adherence to therapy, side effects of medications, and effects of medications on other medications that the patient is taking. A team-based approach to the care and management of patients with HAE is critical to provide optimal care to these patients throughout their lifetime.

In addition to benefitting the individual with HAE, prophylaxis can have a positive impact on families, employers and the health system. Fewer severe attacks and fewer hospital and emergency department visits can translate into fewer lost days of work or school for individuals and their families. Parents and caregivers of children with HAE will experience a reduction in their burden of caregiving. In addition, there will be a predictable decrease in the utilization of the health system for acute care of HAE attacks. While there are no guarantees that these cost savings will offset the cost of the medication itself, these system level gains will only occur if the medications are accessible to the individuals with HAE who need them. This is especially true for rare disease treatments, which are generally the most expensive per unit of treatment.

What changes

• Treatment conversations and prescribing practices may become more straightforward because clinicians can consider berotralstat for a broader set of patients without rigidly tying the decision to a recent attack count. The evidence that baseline attack frequency does not materially alter the drug’s preventive effect supports offering prophylaxis to patients who meet clinical severity criteria, have significant anxiety about attacks, or who prefer oral therapy. Shared decision making remains key: clinicians should discuss expected reductions, the potential for breakthrough attacks, side effect profiles, and monitoring plans so patients make informed choices aligned with their goals.
• Monitoring approaches and follow up protocols will evolve to reflect real world use and long term management. When initiating berotralstat, clinicians typically document baseline attack frequency, severity, and need for on-demand medications. After starting therapy, regular follow up visits can assess adherence, side effects, and attack logs. Objective tracking of attack frequency and patient reported outcomes such as quality of life and attack severity helps determine whether the chosen strategy meets expectations. For patients who continue to experience frequent or severe attacks despite therapy, clinicians should reassess adherence, drug interactions, and consider adjunctive or alternative prophylactic options.
• Access, reimbursement, and health policy will influence how widely these practice changes translate into patient benefit. Payers and national health systems may define eligibility criteria for prophylactic therapy based on attack frequency, severity, failed prior therapies, or cost effectiveness thresholds. Evidence showing consistent efficacy across baseline rates supports policy arguments for offering prophylaxis more broadly, but budgetary constraints and value assessments vary by setting. Clinicians and patient advocates can use the growing body of data to engage with payers and regulators about coverage criteria, emphasizing that effectiveness is not limited to a narrow baseline subgroup. Health economic analyses that model reductions in emergency care, hospitalizations, and lost productivity are persuasive tools in those discussions.
• Practical care pathways should incorporate patient education and individualized risk assessment. For successful integration, clinics could adopt standardized entry assessments that include attack history, impact on daily life, prior prophylaxis or on-demand use, comorbidities, and patient preferences. Counseling on expected timeline to benefit is important: many patients see reductions in attack frequency within weeks to months, but the full preventive effect may evolve with continued use. Education should also cover how to manage breakthrough attacks, when to seek urgent care for airway symptoms, and the importance of maintaining rescue medication if prescribed. These practical steps help patients feel secure and supported while on long term prophylaxis.
• Real world evidence collection and registry participation will continue to shape best practices. Ongoing observational studies and registries capture diverse patient experiences outside clinical trials and can examine effectiveness in patients with comorbidities, different ages, or concomitant medications. These data help refine guidance on who benefits most and how to manage rare adverse events. Clinicians are encouraged to contribute to registries and to report notable outcomes so that collective experience improves care for the broader HAE community.
• Research priorities include head to head comparisons, long term safety surveillance, and quality of life outcomes. While randomized trials demonstrated clear efficacy and extension studies support durability, comparing berotralstat directly to other prophylactic options and studying long term clinical and economic outcomes will further inform personalized therapy selection. Trials should include diverse populations and younger patients when appropriate so guidance reflects real world heterogeneity. Conclusion The growing evidence that berotralstat reduces hereditary angioedema attacks consistently across different baseline attack frequencies strengthens confidence in its role as a reliable long term prophylactic therapy. For patients living with HAE, this consistency provides reassurance that treatment effectiveness is not dependent on how many attacks they experienced before starting therapy. Whether a patient has frequent monthly attacks or a more variable pattern, the available data indicate that berotralstat can deliver meaningful reductions in attack rates. This simplifies treatment planning and reduces uncertainty for both patients and clinicians when deciding on preventive strategies. From a clinical perspective, the ability to rely on stable efficacy across subgroups supports a more patient centered approach to care. Instead of focusing narrowly on a specific attack threshold, healthcare providers can evaluate the broader impact of HAE on quality of life, psychological stress, work productivity, and risk of severe episodes. Patients who may not meet historically strict attack frequency criteria but still experience significant anxiety or functional impairment can now be considered for prophylaxis with greater confidence. This shift encourages individualized decision making based on overall disease burden rather than a single numerical cutoff. For the healthcare system, consistent efficacy across baseline attack frequencies may also contribute to more predictable outcomes and resource planning. When prophylactic therapy reliably reduces attacks, emergency visits, hospital admissions, and urgent airway interventions may decrease over time. This not only improves patient safety but also reduces pressure on acute care services. Over the long term, effective prevention can help shift the management of HAE from reactive emergency treatment to proactive outpatient care, which is generally safer, less stressful, and more cost effective. Ultimately, the consistent performance of berotralstat regardless of baseline attack frequency represents meaningful progress in the management of hereditary angioedema. It reduces complexity in clinical decision making, empowers patients with a convenient oral preventive option, and supports a more comprehensive strategy focused on long term disease control. As research continues and access expands, therapies like berotralstat have the potential to further transform HAE care, improving stability, confidence, and quality of life for those living with this rare but serious condition.

References:

https://www.ncbi.nlm.nih.gov/books/NBK596626/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276548/ https://pubmed.ncbi.nlm.nih.gov/34370872/